期刊
CURRENT PHARMACEUTICAL DESIGN
卷 18, 期 19, 页码 2793-2803出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212800626238
关键词
Epothilones; cytoskeleton; class III beta-tubulin; cell survival; ovarian cancer
资金
- AIRC (Associazione Italiana Ricerca sul Cancro)
Among the drugs targeting microtubule functions by interfering with tubulin subunits, epothilones represent a class of anticancer agents which recently entered clinical development. Although epothilones share mechanisms of action similar to taxanes, they have non-overlapping mechanisms of resistance; in particular, while overexpression of class III beta-tubulin plays a major role in taxane resistance, epothilones display their highest efficacy in class III beta-tubulin overexpressing malignancies. Three compounds belonging to this family (patupilone, ixabepilone and sagopilone), have been actively investigated in clinical trials, and some of them are at an advanced stage of development. This review provides a comprehensive analysis of the available literature on epothilones, focusing on their clinical development and potential as an additional weapon in the arsenal against tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据